Search This Blog

Thursday, January 31, 2019

Fasting ramps up human metabolism

A study by the G0 Cell Unit and Kyoto University researchers suggests that fasting, which puts the body in ‘starvation mode,’ leads to fuel substitution, antioxidation, increased mitochondrial activation and altered signal transduction.
Credit: OIST
Fasting may help people lose weight, but new research suggests going without food may also boost human metabolic activity, generate antioxidants, and help reverse some effects of aging. Scientists at the Okinawa Institute of Science and Technology Graduate University (OIST) and Kyoto University identified 30 previously-unreported substances whose quantity increases during fasting and indicate a variety of health benefits.
“We have been researching aging and metabolism for many years and decided to search for unknown health effects in human fasting,” said Dr. Takayuki Teruya, first author of the paper and a technician in the OIST G0 Cell Unit, led by Prof. Mitsuhiro Yanagida. “Contrary to the original expectation, it turned out that fasting induced metabolic activation rather actively.”
The study, published January 29, 2019 in Scientific Reports, presents an analysis of whole human blood, plasma, and red blood cells drawn from four fasting individuals. The researchers monitored changing levels of metabolites — substances formed during the chemical processes that grant organisms energy and allow them to grow. The results revealed 44 metabolites, including 30 that were previously unrecognized, that increased universally among subjects between 1.5- to 60-fold within just 58 hours of fasting.
In previous research, the G0 Cell Unit identified various metabolites whose quantities decline with age, including three known as leucine, isoleucine, and ophthalmic acid. In fasting individuals, these metabolites increase in level, suggesting a mechanism by which fasting could help increase longevity.
“These are very important metabolites for maintenance of muscle and antioxidant activity, respectively,” said Teruya. “This result suggests the possibility of a rejuvenating effect by fasting, which was not known until now.”
Metabolites Give Clues to Mechanism and Health Effects
The human body tends to utilize carbohydrates for quick energy — when they’re available. When starved of carbs, the body begins looting its alternate energy stores. The act of “energy substitution” leaves a trail of evidence, namely metabolites known as butyrates, carnitines, and branched-chain amino acids. These well-known markers of energy substitution have been shown to accumulate during fasting.
But fasting appears to elicit effects far beyond energy substitution. In their comprehensive analysis of human blood, the researchers noted both established fasting markers and many more. For example, they found a global increase in substances produced by the citric acid cycle, a process by which organisms release energy stored in the chemical bonds of carbohydrates, proteins and lipids. The marked increase suggests that, during fasting, the tiny powerhouses running every cell are thrown into overdrive.
Fasting also appeared to enhance the metabolism of purine and pyrimidine, chemical substances which play key roles in gene expression and protein synthesis. The finding suggests fasting may reprogram which proteins cells build at what time, thus altering their function. The change may promote homeostasis in cells, or serve to edit their gene expression in response to environmental influences.
When metabolized, purine and pyrimidine also boost the body’s production of antioxidants. Several antioxidants, such as ergothioneine and carnosine, were found to increase significantly over the 58-hour study period. Antioxidants serve to protect cells from free radicals produced during metabolism. Products of a metabolic pathway called the “pentose phosphate pathway” also stay the harmful effects of oxidation, and were similarly seen to increase during fasting, but only in plasma.
Newfound Health Benefits of Fasting?
The authors suggest that these antioxidative effects may stand as the body’s principal response to fasting, as starvation can foster a dangerously oxidative internal environment. Their exploratory study provides the first evidence of antioxidants as a fasting marker. In addition, the study introduces the novel notion that fasting might boost production of several age-related metabolites, abundant in young people, but depleted in old.
“Recent aging studies have shown that caloric restriction and fasting have a prolonging effect on lifespan in model animals…but the detailed mechanism has remained a mystery,” said Teruya. “It might be possible to verify the anti-aging effect from various viewpoints by developing exercise programs or drugs capable of causing the metabolic reaction similar to fasting.”
The findings expand on established ideas of what fasting could do for human health. The next step would be to replicate these results in a larger study, or investigate how the metabolic changes might be triggered by other means.
“People are interested in whether human beings can enjoy the effects of prevention of metabolic diseases and prolonging life span by fasting or caloric restriction, as with model animals,” said Teruya. “Understanding the metabolic changes caused by fasting is expected to give us wisdom for maintaining health.”
Story Source:
Materials provided by Okinawa Institute of Science and Technology (OIST) Graduate UniversityNote: Content may be edited for style and length.

Journal Reference:
  1. Takayuki Teruya, Romanas Chaleckis, Junko Takada, Mitsuhiro Yanagida, Hiroshi Kondoh. Diverse metabolic reactions activated during 58-hr fasting are revealed by non-targeted metabolomic analysis of human bloodScientific Reports, 2019; 9 (1) DOI: 10.1038/s41598-018-36674-9

Edwards Lifesciences sees Q1 adjusted EPS $1.15-$1.25, consensus $1.30

Sees Q1 revenue $950M-$1.01B, consensus $997.57M.
https://thefly.com/landingPageNews.php?id=2857251

LHC Group, UNity Health announce joint venture in Arkansas

LHC Group and Unity Health announced finalization of an equity partnership agreement to purchase and share ownership of two home health providers in Arkansas: Unity Health – White County Medical Center Home Health in Searcy and Unity Health – Harris Medical Center Home Health in Newport. The agencies serve patients and families in their respective communities and the Northeast Arkansas region with in-home healthcare. With the closing of the joint venture agreement, LHC Group will oversee the day-to-day operations of both agencies which will continue service from their current locations under a new name: Unity Health HomeCare. LHC Group expects annualized revenue from this joint venture of approximately $4M and that it will not materially affect its 2019 diluted earnings per share.
https://thefly.com/landingPageNews.php?id=2857259

Corcept Therapeutics reports Q4 revenue $66.8M, consensus $70.42M

https://thefly.com/landingPageNews.php?id=2857204

Onconova to present at key opinion leaders meet

Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced it will host a KOL breakfast for security analysts and institutional investors on Thursday, February 7, 2019, in New York City.
The event will include presentations by Lewis Silverman, MD, Associate Professor of Medicine and Director of the Translational Research Center for the Myelodysplastic Syndrome in the Division of Hematology/Oncology/Tisch Cancer Institute and Rajwanth Veluswamy, MD, MSCR, Assistant Professor of Medicine, Thoracic Oncology, Tisch Cancer Institute, Institute for Translational Epidemiology, Icahn School of Medicine, Mount Sinai Health System. In addition, Steven Fruchtman, MD, President and Chief Executive Officer of Onconova, will present a Company overview and detailed information from the Company’s Phase 2 rigosertib trial and the Company’s clinical strategy and near-term milestones.
Presentations will begin at 8:00 a.m. Eastern Standard Time. A live and archived audio and slide webcast of the event will be available on Onconova’s Corporate Events and Presentations page. Following the presentations, all speakers will be available for questions. This on-site event is open to analysts and institutional investors only.  Kindly RSVP in advance if you would like to attend in person, as space is limited. To request a spot, please send an email to ir@onconova.us.

Novus gains on advancement of lead med

Thinly traded nano cap Novus Therapeutics (NVUS +14.9%) is up on average volume following its updates on clinical trials supporting lead drug OP0201.
Phase 1 trials: first dose cohort completed in adult safety and tolerability study (C-002). Screening for second higher dose cohort underway. Initial screening underway in single-dose safety and pharmacodynamics study (C-001). Data from both trials should be available in Q2. Enrollment completed in single-dose safety and preliminary efficacy study (C-004) in adults with acute otitis media (ear infection) with data expected later this quarter.
A Phase 2a study, C-006, in infants and children with acute otitis media has been added. Enrollment will commence in the coming weeks with topline results expected in H2.

Small Rise in Hemoglobin A1c in Switch to Human Insulin in Type 2 Diabetes

Switching from analogue to human insulin is associated with a small increase in hemoglobin A1c (HbA1c) levels, according to a study published in the Jan. 29 issue of the Journal of the American Medical Association.
Jing Luo, M.D., M.P.H., from Brigham and Women’s Hospital in Boston, and colleagues examined the correlation between glycemic control and implementation of a health plan-based intervention of switching older adults with type 2 diabetes from analogue to human insulin. Data were included for 14,635 members who filled 221,866 insulin prescriptions over three years.
The researchers found that the start of the intervention correlated with a 0.14 percent overall HbA1c-level increase and a 0.02 percent slope change. No significant differences were noted in changes in the level or slope of mean HbA1c after completion of the intervention versus the intervention period. For serious hypoglycemic events, no significant correlation was found between the start of the intervention and the level or slope of change; no significant differences were seen in the level and slope for the postintervention versus the intervention period. No significant correlation was seen between the start of the intervention and a level or slope change for the rate of serious hyperglycemic events.
“Our study provides real-world evidence from clinical practice that should reassure patients, providers, and payors that it may be possible to switch to an older less expensive insulin to bring down costs while preserving quality of care,” Luos said in a statement.
Several authors disclosed financial ties to the pharmaceutical and medical device industries.